Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Receives Average Rating of “Moderate Buy” from Brokerages

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) has been assigned an average rating of “Moderate Buy” from the eleven brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $42.4286.

A number of analysts recently commented on DMRA shares. Guggenheim restated a “buy” rating and set a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. HC Wainwright initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday. They issued a “buy” rating and a $45.00 price objective for the company. Wedbush started coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, May 28th. They set an “outperform” rating and a $35.00 target price on the stock. TD Cowen began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday. They set a “buy” rating on the stock. Finally, UBS Group started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 price target for the company.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Institutional investors and hedge funds have recently bought and sold shares of the company. Two Sigma Investments LP bought a new position in Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at $76,000. Virtu Financial LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the third quarter worth $49,000. Connective Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the third quarter valued at $100,000. Sigma Planning Corp purchased a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $334,000. Finally, Geode Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $266,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of DMRA opened at $21.36 on Friday. The business has a 50-day moving average of $24.59 and a 200 day moving average of $25.37. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $2.45 and a fifty-two week high of $38.33. The firm has a market cap of $1.31 billion, a P/E ratio of -3.83 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.23). As a group, research analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.13 earnings per share for the current fiscal year.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.